# T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

> **NCT04351230** · PHASE2 · WITHDRAWN · sponsor: **Academic and Community Cancer Research United**

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- HER2 Positive Breast Carcinoma
- Metastatic Breast Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8

## Interventions

- **DRUG:** Abemaciclib
- **BIOLOGICAL:** Trastuzumab Emtansine

## Key facts

- **NCT ID:** NCT04351230
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-11-11
- **Primary completion:** 2022-02-16
- **Final completion:** 2022-02-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** There are no patients enrolled on this study and all efforts are being discontinued
- **Last updated:** 2022-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04351230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04351230, "T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04351230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*